tiprankstipranks
Trending News
More News >
Annovis Bio (ANVS)
NYSE:ANVS

Annovis Bio (ANVS) AI Stock Analysis

Compare
646 Followers

Top Page

AN

Annovis Bio

(NYSE:ANVS)

Rating:35Underperform
Price Target:
Annovis Bio's overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.
Positive Factors
Analyst Recommendation
Analysts have initiated a Buy rating for Annovis Bio, Inc. with a price target of $25.00.
Clinical Trial Progress
The company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease, which is seen as a significant step forward.
Regulatory Milestone
Positive results from the 6-month readout could potentially support an NDA filing for symptomatic Alzheimer's disease.
Negative Factors
Broad Market Challenges
Broad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.
Equity Financing Impact
The 12-month price target is reduced to $12 from the prior $30 per share to reflect the impact of the most recent equity financing, future potential equity issuances, and the exercise of warrants.
Risk Factors
Risks include, but are not limited to: failure to initiate trials in a timely manner, negative clinical results for buntanetap in Parkinson's disease and/or Alzheimer's disease, inability to establish partnerships to commercialize buntanetap, failure to secure approval for buntanetap and/or other pipeline candidates, slower-than-anticipated market uptake, and possible medium-term dilution risk.

Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)

Annovis Bio Business Overview & Revenue Model

Company DescriptionAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
How the Company Makes MoneyAnnovis Bio generates revenue primarily through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials and eventually receiving regulatory approval for commercialization. Once a drug is approved, Annovis Bio may earn money through direct sales, licensing agreements, or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, the company may also receive funding from grants or collaborative research agreements with other institutions. However, as a clinical-stage company, Annovis Bio may not currently have significant revenue streams from commercialized products.

Annovis Bio Financial Statement Overview

Summary
Annovis Bio's financial performance is weak due to zero revenue and increasing net losses, which is common for early-stage biotech firms. The balance sheet is hampered by negative equity at times, despite having no debt. Cash flows are negative, indicating reliance on external funding.
Income Statement
10
Very Negative
Annovis Bio has reported zero revenue consistently since 2019, which is a significant concern for sustainability. The company has faced increasing net losses, with the latest annual report showing a net loss of approximately $24.59 billion. The lack of revenue and growing losses reflect poor financial health from an income perspective, typical for early-stage biotechnology firms focusing on R&D without a commercialized product.
Balance Sheet
30
Negative
The balance sheet shows that Annovis Bio has no debt, which is a positive sign. However, the company has a negative equity at times and fluctuating stockholders' equity, indicating financial instability. The equity ratio has been erratic, and the lack of tangible revenue-generating assets further complicates its financial stability.
Cash Flow
20
Very Negative
Operating cash flows have been consistently negative, reflecting the company's ongoing investments in operations without incoming cash flow from sales. While financing activities have provided some relief, the overall cash flow situation highlights a dependency on external funding to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-25.17M-22.74M-45.03M-25.51M-14.50M-5.46M
Net Income-29.06M-24.59B-56.20M-25.33M-14.49M-5.46M
Balance Sheet
Total Assets26.74M13.93M10.21M36.02M46.00M8.12M
Cash, Cash Equivalents and Short-Term Investments22.24M10.55M5.75M28.38M45.69M8.07M
Total Debt0.000.000.000.000.000.00
Total Liabilities2.68M4.62M17.96M7.70M1.51M578.38K
Stockholders Equity24.05M9.31M-7.75M28.32M44.49M7.54M
Cash Flow
Free Cash Flow-8.11B-21.89B-39.97M-17.31M-9.13M-3.97M
Operating Cash Flow-8.11B-21.89B-39.97M-17.31M-9.13M-3.97M
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow19.81B26.69B17.34M4.61K46.74M12.04M

Annovis Bio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.53
Price Trends
50DMA
2.23
Positive
100DMA
1.97
Positive
200DMA
4.27
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
52.57
Neutral
STOCH
39.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Positive. The current price of 2.53 is below the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.23, and below the 200-day MA of 4.27, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 52.57 is Neutral, neither overbought nor oversold. The STOCH value of 39.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANVS.

Annovis Bio Risk Analysis

Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Annovis Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
42
Neutral
$22.12M-70.06%146.47%57.85%
41
Neutral
$35.16M-853.05%34.97%
38
Underperform
$27.94M78.50%55.52%
35
Underperform
$22.55M-246.21%44.38%
35
Underperform
$45.99M-280.78%68.75%
$27.16M-197.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANVS
Annovis Bio
2.53
-9.55
-79.06%
GBIO
Generation Bio
0.35
-1.98
-84.98%
PYPD
PolyPid
3.43
-0.59
-14.68%
BCAB
BioAtla
0.39
-1.03
-72.54%
COEP
Coeptis Therapeutics Holdings
8.28
2.64
46.81%
INKT
MiNK Therapeutics
7.20
-1.50
-17.24%

Annovis Bio Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
Annovis Bio Faces NYSE Non-Compliance Notice
Negative
Mar 27, 2025

On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.

Product-Related Announcements
Annovis Bio Launches Phase 3 Alzheimer’s Study
Positive
Feb 5, 2025

On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025